Seattle Diagnostics Company Immunexpress Bags $40 Million to Beef Up Sales and Marketing Payroll

Seattle diagnostics company Immunexpress is working to whittle sepsis screening time down to an hour – and is in the midst of a $40 million Series C to do so, CEO Roz Brandon says. Its approach is to measure a patient’s septic immune response – parting ways with the current norm of seeking out sepsis-causing pathogens in the blood.

Immunexpress is expecting that its first test, called SeptiCyte, will receive FDA clearance by the close of 2015. It’s currently ramping up for commercialization, and plans to use the C round to build out a sales and marketing force.

Help employers find you! Check out all the jobs and post your resume.

Back to news